Time For Big Pharma And Emerging Markets To Embrace Global Health Diplomacy – Report
This article was originally published in PharmAsia News
Executive Summary
A report argues that multinational drug companies need to pursue health diplomacy in emerging markets in order to reap the benefits of greater public health care spending and rising incomes – including figuring out better ways to widen access to some of the world’s most expensive medicines.